Royal Bank of Canada Cuts SAGE Therapeutics (NASDAQ:SAGE) Price Target to $100.00

SAGE Therapeutics (NASDAQ:SAGE) had its price target lowered by Royal Bank of Canada from $190.00 to $100.00 in a research note published on Friday morning, Briefing.com Automated Import reports. The firm currently has an outperform rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also weighed in on the company. Leerink Swann upgraded SAGE Therapeutics from an underperform rating to a market perform rating and set a $63.00 price target for the company in a research report on Friday. BMO Capital Markets restated an outperform rating and set a $92.00 price objective on shares of SAGE Therapeutics in a report on Friday. Svb Leerink raised shares of SAGE Therapeutics from an underperform rating to a market perform rating in a research note on Friday. ValuEngine upgraded shares of SAGE Therapeutics from a buy rating to a strong-buy rating in a report on Thursday. Finally, Guggenheim decreased their target price on shares of SAGE Therapeutics from $200.00 to $110.00 and set a buy rating for the company in a report on Thursday. One research analyst has rated the stock with a sell rating, six have given a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus price target of $128.81.

SAGE opened at $64.46 on Friday. The firm has a market cap of $3.34 billion, a PE ratio of -7.98 and a beta of 2.52. The company has a quick ratio of 12.67, a current ratio of 12.67 and a debt-to-equity ratio of 0.03. The business has a fifty day simple moving average of $142.30 and a 200-day simple moving average of $160.81. SAGE Therapeutics has a fifty-two week low of $56.50 and a fifty-two week high of $193.56.

SAGE Therapeutics (NASDAQ:SAGE) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($3.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.41) by ($0.07). The company had revenue of $3.57 million for the quarter, compared to analyst estimates of $2.52 million. SAGE Therapeutics had a negative return on equity of 60.00% and a negative net margin of 12,931.34%. During the same period last year, the firm earned ($2.63) earnings per share. The firm’s revenue for the quarter was up 35600.0% on a year-over-year basis. On average, equities research analysts anticipate that SAGE Therapeutics will post -13.77 EPS for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Amundi Pioneer Asset Management Inc. increased its stake in SAGE Therapeutics by 40.7% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 136,459 shares of the biopharmaceutical company’s stock valued at $21,704,000 after buying an additional 39,447 shares during the period. Commonwealth Equity Services LLC lifted its position in SAGE Therapeutics by 4.5% in the 2nd quarter. Commonwealth Equity Services LLC now owns 1,772 shares of the biopharmaceutical company’s stock worth $324,000 after buying an additional 77 shares in the last quarter. Creative Planning boosted its stake in shares of SAGE Therapeutics by 13.0% during the 2nd quarter. Creative Planning now owns 2,563 shares of the biopharmaceutical company’s stock valued at $469,000 after buying an additional 294 shares during the period. Janney Capital Management LLC boosted its stake in shares of SAGE Therapeutics by 18.2% during the 2nd quarter. Janney Capital Management LLC now owns 4,387 shares of the biopharmaceutical company’s stock valued at $803,000 after buying an additional 675 shares during the period. Finally, Janney Montgomery Scott LLC grew its holdings in shares of SAGE Therapeutics by 5.0% during the 2nd quarter. Janney Montgomery Scott LLC now owns 4,557 shares of the biopharmaceutical company’s stock valued at $834,000 after acquiring an additional 219 shares in the last quarter.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

Featured Article: Book Value Per Share in Stock Trading

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.